96 Tests PN: B111389
45x Ab-conjugated beads (S4P4 - human IFNβ Ab-bead). PN: B111389A. One vial containing 100 µL of anti-human IFNβ conjugated to AimPlex Bead S4P4.
25x Biotin-detection Ab (human IFNβ Biotin-dAb). PN: B111389B. One vial containing 100 µL of biotinylated anti-human IFNβ.
Lyophilized Standard Mix-Human Group 4 Panel B, 10-Plex. PN: HG40010. One vial containing lyophilized recombinant human GASP-1, IFNβ, ANGPT-1, Insulin, Leptin, MIF, Resistin, Survivin, TGFα, and TPO. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human IFNβ. Can be multiplexed with other analytes in Human Group 4. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 2 pg/mL
LLOQ: < 5 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 4: Negligible
Sample volume: 15 µL/test
IFN-beta is produced mainly by fibroblasts and some epithelial cell types. The synthesis of IFN-beta can be induced by common inducers of interferons, including viruses, double-stranded RNA, and micro-organisms. It is induced also by some cytokines such as TNF and IL1. IFN-beta is involved in the regulation of unspecific humoral immune responses and immune responses against viral infections. IFN-beta stimulates the activity of NK-cells and hence also antibody-dependent cytotoxicity. The activity of T suppressor cells elicited by several stimuli is stimulated also by IFN-beta. IFN-beta enhances the synthesis of the low affinity IgE receptor CD23. In activated monocytes IFN-beta induces the synthesis of neopterin. It also enhances serum concentrations of Beta-2-Microglobulin. IFN-beta selectively inhibits the expression of some mitochondrial genes. IFN-beta shows anti-proliferative activity against a number of cell lines established from solid tumors. IFN-beta can be used for topic treatment of condylomata acuminata. It is also suitable for the prophylactic use following surgical removal of large condylomas. Some studies suggest that IFN-beta tends to prevent disease activity in patients with multiple sclerosis. IFN-beta is a lipophilic molecule that should be particularly useful for local tumor therapy due to its specific pharmacokinetics. IFN-beta also appears to be very promising for the adjuvant therapy of malignant melanomas with a high potential for metastasis. Response rates have been reported to be improved by combining IFN-beta with antineoplastic agents or other cytokines.
Buzzi F et al Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Research 12: 869-871 (1992);
Capalbo M et al Treatment of chronic hepatitis B with beta interferon given intramuscularly: a pilot study. Italian Journal of Gastroenterology 24: 203-205 (1992);
Duggan DB et al A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. Journal of Immunotherapy 12: 115-122 (1992);
Fierlbeck G et al [Intralesional therapy of melanoma metastases with recombinant interferon-beta] Hautarzt 43: 16-21 (1992);